Cardiovascular disease and toxicities related to HIV infection and its therapies

Expert Opinion on Drug Safety

Volumn 4, Issue 6, 2005, Pages 1017-1025

  Zareba, Karolina M ^a   Miller, Tracie L ^b,c   Lipshultz, Steven E ^b,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

AIDS; Cardiomyopathy; Cardiotoxicity; Dyslipidaemia; Exercise; Highly active antiretroviral theraphy (HAART); HIV

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; DOXORUBICIN; FENOFIBRATE; FLUINDOSTATIN; FOSCARNET SODIUM; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INDINAVIR; MACROLIDE; NUCLEOSIDE ANALOG; PENTAMIDINE; PLACEBO; PRAVASTATIN; PROSTACYCLIN; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNINDEXED DRUG; VASODILATOR AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROTIC PLAQUE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DYSLIPIDEMIA; ENDOCARDITIS; EXERCISE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; KAPOSI SARCOMA; LIVER TOXICITY; METABOLIC SYNDROME X; MUSCLE DISEASE; MYOCARDITIS; MYOSITIS; OBESITY; PATHOGENESIS; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; SURVIVAL; TORSADE DES POINTES; WASTING SYNDROME;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE THERAPY; HIV INFECTIONS; HUMANS; PREVALENCE; RISK FACTORS;

EID: 27944441787     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.6.1017     Document Type: Review

References (82)

1. RAFFANTI SP, CHIARAMIDA AJ, SEN P et al.: Assessment of cardiac function in patients with the acquired immunodeficiency syndrome. Chest (1988) 93:592-594.
2. 2 HIV study. J. Pediatr. (2002) 141:327-334.
3. 2 HIV): a cohort study. Lancet (2002) 360:368-373.
4. KOLTER DP: Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy. AIDS Read. (2003) 13:S5-S13.
5. CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: Abnormal fat distribution and use of protease inhibitors. Lancet (1998) 351:1736.
6. SHEPHARD, RJ: Exercise, immune function and HIV infection. J. Sports Med. Phys. Fitness (1998) 38(2): 101-110.
7. BOZZETTE SA, AKE CF, TAM HK, CHANG SW, LOUIS TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. (2003) 348:702-710.
8. HERSKOWITZ A, VLAHOV D, WILLOUGHBY S et al.: Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am. J. Cardiol. (1993) 71(11):955-958.
9. LIPSHULTZ SE: Dilated cardiomyopathy in HIV-infected patients. N. Engl. J. Med. (1998) 339:1153-1155.
10. FELKER GM, THOMPSON RE, HARE JM et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. (2000) 342:1077-1084.
11. 2 HIV) Study Group. Circulation (1998) 97:1246-1256.
12. 2 HIV) Study Group. Circulation (2000) 102:1542-1548.
13. PULERWITZ TC, CAPPOLA TP, FELKER GM et al.: Mortality in primary and secondary myocarditis. Am. Heart J. (2004) 147:746-750.
14. LEBECH AM, GERSTOFT J, HESSE B, PETERSEN CL, KJAER A: Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am. Heart J. (2004) 147:482-488.
15. FISHER SD, LIPSHULTZ SE: Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann. N.Y. Acad. Sci. (2001) 946:13-22.
16. FISHER SD, LIPSHULTZ SE: Cardiac disease. In: AIDS Therapy. Dolin R, Masur H, Saag MS (Eds), Churchill-Livingstone, Philadelphia, USA (2002):814-826.
17. KASTEN-SPORTES C, WEINSTEIN C: Molecular mechanisms of HIV cardiovascular disease. In: Cardiology in AIDS. Lipshultz SE (Ed.), Chapman and Hall, New York (1998):265-282.
18. CURRIE PF, GOLDMAN JH, CAFORIO AL et al.: Cardiac autoimmunity in HIV related heart muscle disease. Heart (1998) 79:599-604.
19. CURRIE PF, BOON NA: Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS (2003) 17:S21-S28.
20. LUGINBUHL LM, ORAV EJ, MCINTOSH K, LIPSHULTZ SE: Cardiac morbidity and related mortality in children with HIV infection. JAMA (1993) 269:2869-2875.
21. AL-ATTAR I, ORAV EJ, EXIL V, VLACH SA, LIPSHULTZ SE: Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. JACC (2003) 41:1598-605.
22. LIPSHULTZ SE, ORAV EJ, SANDERS SP, COLAN SD: Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation (1995) 92:2220-2225.
23. LIPSHULTZ SE, FISHER SD, LAI WW MILLER TL: Cardiovascular monitoring and therapy for HIV-infected patients. Ann. NY Acad. Sci. (2001) 946:236-273.
24. FISHER SD, BOWLES NE, TOWBIN JA, LIPSHULTZ SE: Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS (2003) 17:S29-S35.
25. LIPSHULTZ SE, FISHER SD, LAI WW, MILLER TL: Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS (2003) 17:S96-S122.
26. MESA RA, EDELL ES, DUNN WF, EDWARDS WD: Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin. Proc. (1998) 73:37-45.
27. PELLICELLI AM, PALMIERI F, D'AMBROSIO C et al.: Role of human immunodeficiency virus in primary pulmonary hypertension-case reports. Angiology (1998) 49(12):1005-1011.
28. SEOANE L, SHELLITO J, WELSH D, DE BOISBLANC BP: Pulmonary hypertension associated with HIV infection. South Med. J. (2001) 94(6):635-639.
29. AGUILAR RV, FARBER HW: Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2000) 162:1846-1850.
30. HEIDENREICH PA, EISENBERG MJ, KEE LL et al.: Pericardial effusion in AIDS. Incidence and survival. Circulation (1995) 92:3229-3234.
31. RERKPATTANAPIPAT R, WONGPRAPARUT N, JACOBS LE, KOTLER MN: Cardiac manifestations of acquired immunodeficiency syndrome. Arch. Intern. Med. (2000) 160:602-608.
32. GOWDA RM, KHAN IA, MEHTA NJ, GOWDA MR, SACCHI TJ, VASAVADA BC: Cardiac tamponade in patients with human immunodeficiency virus disease. Angiology (2003) 54:469-474.
33. VALENCIA ORTEGA ME, GUINEA J, ENRIQUE A, ORTEGA G, MORENO V, GONZALEZ LAHOZ J: Study of 42 cases of infective endocarditis in the HAART era in Spain. Clin. Microbiol. Infect. (2003) 9:1073-1075.
34. DANIEL WG, MUGGE A, MARTIN RP et al.: Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N. Engl. J. Med. (1991) 324:795-800.
35. FANTONI M, AUTORE C, DEL BORGO C: Drugs and cardiotoxicity in HIV and AIDS. Ann. NY Acad. Sci. (2001) 946:179-199.
36. WONG JCL, LIPSHULTZ SE: Cardiovascular complications of pharmacotherapeutic agents (excluding the antiretrovirals) in HIV-infected patients. In: Cardiology in AIDS. Lipshultz SE (Ed.), Chapman and Hall, New York (1998):331-343.
37. PUGLIESE A, ISNARDI D, SAINI A et al.: Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J. Infect. (2000) 40:282-284.
38. DUBE MP, SPRECHER D, HENRY WK et al.: Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. (2000) 31:1216-1224.
39. CURRIER JS: Cardiovascular risk associated with HIV therapy. J. Acquir. Immune. Defic. Syndr. (2002) 31:S16-S23.
40. GRUNFELD C, KOTLER DP, HAMADEH R et al.: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. (1989) 86(1):27-31.
41. PURNELL JQ, ZAMBON A, KNOPP RH et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS (2000) 14(1):51-57.
42. VAN DER VALK M, REISS P, MOLHUIZEN H et al.: Nevirapine containing potent antiretroviral therapy results in an anti-atherogenic plasma lipid profile: results from the atlantic trial. 8th Conference on Retroviruses and Opportunistic Infections, USA (2001).
43. MAGGI P, SERIO G, EPIFANI G et al.: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS (2000) 14(16):F123-F128.
44. DEPAIRON M, CHESSEX S, SUDRE P et al.: Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy. AIDS (2001) 15(3):329-334.
45. FRIIS-MOLLER N, WEBER R, REISS P et al.: Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 17:1179-1193.
46. RICKERTS V, BRODT H, STASZEWSKI S, STILLE W: Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur. J. Med. Res. (2000) 5:329-333.
47. HOLMBERG SD, MOORMAN AC, WILLIAMSON JM et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet (2002) 360:1747-1748.
48. RHEW DC, BERNAL M, AGUILAR D, ILOEJE U, GOETZ MB: Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: A systemic review. Clin. Infect. Dis. (2003) 37:959-972.
49. BERGERSEN BM, SANDVIK L, BRUUN JN, TONSTAD S: Elecvated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:625-630.
50. THE DATA COLLECTION ON ADVERSE EVENTS OF ANTI-HIV DRUGS (DAD) STUDY GROUP: Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. (2003) 349:1993-2003.
51. KLEIN D, SIDNEY S, HURLEY L, IRIBARREN C: Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? 6th Conference on Retroviruses and Opportunistic Infections, USA (1999).
52. MARY-KRAUSE M, COTTE L, SIMON A, PARTISANI M, COSTAGLIOLA D: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 17:2479-86.
53. SCHAMBELAN M, BENSON CA, CARR A et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Acquir. Immune. Defic. Syndr. (2002) 31:257-275.
54. SCEVOLA D, DI MATTEO A, LANZARINI P et al.: Effects of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS (2003) 17:S123-S129.
55. ORRICK JJ, STEINHART CR: Atazanavir. Ann. Pharmacother. (2004) 38. E-published ahead of print.
56. HOFFMANN C, JAEGER H: Cardiology and AIDS-HAART and the consequences. Ann. NY Acad. Sci. (2001) 946:130-144.
57. STEIN JH, KLEIN MA, BELLEHUMEUR JL et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation (2001) 104:257-262.
58. DUBE MP, STEIN JH, FICHTENBAUM CJ et al.: Guidelines for the evaluation and management of dylipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. (2003) 37:613-627.
59. BENESIC A, ZILLY M, KLUGE F et al.: Lipid lowering therapy with Fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy. Comparison of efficacy and interaction with indinavir. Infection (2004) 32:229-233.
60. MOYLE GJ, LLOYD M, REYNOLDS B et al.: Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy. AIDS (2001) 15:1503-8.
61. STEIN JH, MERWOOD MA, BELLEHUMEUR JL et al.: Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am. Heart J. (2004) 147:713-724.
62. BADIOU S, DE BOEVER CM, DUPUY AM, BAILLAT V, CRISTOL JP, REYNES J: Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis (2004) 172:273-279.
63. ERIKSSEN G et al.: Changes in physical fitness and changes in mortality. Lancet (1988) 352:759-62.
64. SHEPARD RJ, SHEK PN: Impact of physical activity and sport on the immune system. Rev. Environ. Health. (1996) 11(3):133-147.
65. CANNON JG, FIELDING RA, FIATARONE MA, ORENCOLE SF, DINARELLO CA, EVANS WJ: Increased interleukin 1 beta in human skeletal muscle after exercise. Am. J. Physiol. (1989) 257:R451-R455.
66. BOAS SR, JOSWIAK ML, NIXON PA et al.: Effects of anaerobic exercise on the immune system in eight- to seventeen-year-old trained and untrained boys. J. Pediatr. (1996) 129(6):846-855.
67. NIEMAN DC: Immune response to heavy exertion. J. Appl. Physiol. (1997) 82(5):1385-1394.
68. RIGSBY LW, DISHMAN RK, JACKSON AW, MACLEAN GS, RAVEN PB: Effects of exercise training on men seropositive for the human immunodeficiency virus-1. Med. Sci. Sports Exerc. (1992) 24(1):6-12.
69. LAPIERRE A: Aerobic exercise training in an AIDS risk group. Int. J. Sports. Med. (1991) 12:S53-S57.
70. MUSTAFA T, SY FS, MACERA CA et al.: Association between exercise and HIV disease progression in a cohort of homosexual men. Ann. Epidemiol. (1999) 9(2):127-131.
71. WEISSMAN JD, CONSTANTINITIS I, HUDGINS P, WALLACE DC: 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients. Neurology (1992) 42:619-623.
72. CHAN IS, NEATON JD, SARAVOLATZ LD, CRANE LR, OSTERBERGER J: Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS. AIDS (1995) 9(10):1145-1151.
73. KOTLER DP, TIERNEY AR, WANG J, PIERSON RN Jr: Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am. J. Clin. Nutr. (1989) 50(3):444-447.
74. ROUBENOFF R, WILSON IB: Effect of resistance training on self-reported physical functioning in HIV infection. Med. Sci. Sports Exerc. (2001) 33(11):1811-1817.
75. SPENCE DW, GALANTINO ML, MOSSBERG KA, ZIMMERMAN SO: Progressive resistance exercise: effect on muscle function and anthropometry of a select AIDS population. Arch. Phys. Med. Rehabil. (1990) 71(9):644-648.
76. ROUBENOFF R, MCDERMOTT A, WOOD M, SURI J: Feasibility of increasing lean body mass in HIV-infected adults sing progressive resistance training. Med. Sci. Sports Exerc. (1998) 30(5):S183.
77. ROUBENOFF R, WEISS L, MCDERMOTT A et al.: A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS (1999) 13(11):1373-1375.
78. JONES SP, DORAN DA, LEATT PB, MAHER B, PIRMOHAMED M: Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS (2001) 15(15):2049-2051.
79. DRISCOLL SD, MEININGER GE, LAREAU MT et al.: Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS (2004) 18:465-473.
80. STRINGER WW: Mechanisms of exercise limitation in HIV+ individuals. Med. Sci. Sports Exerc. (2000) 32:S412-S421.
81. ZAREBA KM, LIPSHULTZ SE: Cardiovascular complications in patients with HIV infection. Curr. Infect. Dis. Rep. (2003) 5(6):513-520.
82. SELIK RM, BYERS RH JR, DWORKIN MS: Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J. Acquir. Immune. Defic. Syndr. (2002) 29:378-387.